Achmea Investment Management B.V. Grows Position in Hologic, Inc. (NASDAQ:HOLX)

Achmea Investment Management B.V. boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 36,197 shares of the medical equipment provider’s stock after buying an additional 2,252 shares during the quarter. Achmea Investment Management B.V.’s holdings in Hologic were worth $2,609,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. FMR LLC increased its holdings in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after acquiring an additional 544,889 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Hologic during the 4th quarter valued at about $27,007,000. Swedbank AB raised its holdings in shares of Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after buying an additional 306,562 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after buying an additional 238,222 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on HOLX shares. Morgan Stanley decreased their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Raymond James reaffirmed an “outperform” rating and issued a $90.00 price target (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Citigroup decreased their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $84.62.

Hologic Stock Up 0.0 %

Hologic stock opened at $60.71 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock has a fifty day moving average of $67.18 and a 200 day moving average of $74.71. The stock has a market cap of $13.62 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a one year low of $60.33 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.